Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection
Public ClinicalTrials.gov record NCT01001754. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection
Study identification
- NCT ID
- NCT01001754
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- ZymoGenetics
- Industry
- Enrollment
- 600 participants
Conditions and interventions
Conditions
Interventions
- PEG-rIL-29 Drug
- Peginterferon alfa-2a Drug
- Ribavirin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Oct 31, 2010
- Completion
- Apr 30, 2012
- Last update posted
- Dec 4, 2011
2010 – 2012
United States locations
- U.S. sites
- 29
- U.S. states
- 17
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Beverly Hills | California | — | — |
| Not listed | Coronado | California | 92118 | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Palm Springs | California | 92262 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Englewood | Colorado | 80113 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Lutherville | Maryland | 21093 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | St Louis | Missouri | 63104 | — |
| Not listed | Newark | New Jersey | — | — |
| Not listed | Albuquerque | New Mexico | 87131 | — |
| Not listed | Manhasset | New York | 11030 | — |
| Not listed | New York | New York | 10021 | — |
| Not listed | Charlotte | North Carolina | 28207 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Statesville | North Carolina | 28677 | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Arlington | Texas | 76012 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | Salt Lake City | Utah | 84132 | — |
| Not listed | Fairfax | Virginia | 22031 | — |
| Not listed | Newport News | Virginia | — | — |
| Not listed | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01001754, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 4, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01001754 live on ClinicalTrials.gov.